James Howard, MD, PhD

  1. Howard JF, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Smilowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI, RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Neurology 2023. PMID: 37059508


  2. Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard JF, CHAMPION MG Study Group. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. Journal of neurology 2023. PMID: 37103755


  3. Guptill JT, Benatar M, Granit V, Habib AA, Howard JF, Barnett-Tapia C, Nowak RJ, Lee I, Ruzhansky K, Dimachkie MM, Cutter GR, Kaminski HJ. Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. Neurology 2023. PMID: 37076302


  4. Whitehead N, Erickson SW, Cai B, McDermott S, Peay H, Howard JF, Ouyang L, Muscular Dystrophy Surveillance, Tracking and Research Network. Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States. Orphanet journal of rare diseases 2023. PMID: 36949506


  5. Masi G, Pham MC, Karatz T, Oh S, Payne AS, Nowak RJ, Howard JF, Guptill JT, Juel VC, O'Connor KC. Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis. Annals of clinical and translational neurology 2023. PMID: 36924454


  6. Vu T, Ortiz S, Katsuno M, Annane D, Mantegazza R, Beasley KN, Aguzzi R, Howard JF. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. Journal of neurology 2023. PMID: 36890354


  7. Mann JR, Zhang Y, McDermott S, Wang Y, Cai B, Conway KM, Paramsothy P, Royer J, Venkatesh S, Howard JF, Ciafaloni E. Racial and ethnic differences in timing of diagnosis and clinical services received in Duchenne Muscular Dystrophy. Neuroepidemiology 2023. PMID: 36623491


  8. Sanchez JA, Traub R, Trau SP, Howard JF. Electrodiagnostic Findings in Riboflavin Transporter Deficiency Type 2. Journal of clinical neuromuscular disease 2022. PMID: 35608644


  9. Paramsothy P, Wang Y, Cai B, Conway KM, Johnson NE, Pandya S, Ciafaloni E, Mathews KD, Romitti PA, Howard JF, Riley C. Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking, and Research Network. Neuromuscular disorders : NMD 2022. PMID: 35597713


  10. Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Speed C, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Griggs RC, FOR-DMD Investigators of the Muscle Study Group, Straub V, van Ruiten H, Childs AM, Ciafaloni E, Shieh PB, Spinty S, Maggi L, Baranello G, Butterfield RJ, Horrocks IA, Roper H, Alhaswani Z, Flanigan KM, Kuntz NL, Manzur A, Darras BT, Kang PB, Morrison L, Krzesniak-Swinarska M, Mah JK, Mongini TE, Ricci F, von der Hagen M, Finkel RS, O'Reardon K, Wicklund M, Kumar A, McDonald CM, Han JJ, Joyce N, Henricson EK, Schara-Schmidt U, Gangfuss A, Wilichowski E, Barohn RJ, Statland JM, Campbell C, Vita G, Vita GL, Howard JF, Hughes I, McMillan HJ, Pegoraro E, Bello L, Burnette WB, Thangarajh M, Chang T. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA 2022. PMID: 35381069


  11. Rumsey JW, Lorance C, Jackson M, Sasserath T, McAleer CW, Long CJ, Goswami A, Russo MA, Raja SM, Gable KL, Emmett D, Hobson-Webb LD, Chopra M, Howard JF, Guptill JT, Storek MJ, Alonso-Alonso M, Atassi N, Panicker S, Parry G, Hammond T, Hickman JJ. Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies. Advanced therapeutics 2022. PMID: 36211621


  12. Wang Y, Guo L, Yin X, McCarthy EC, Cheng MI, Hoang AT, Chen HC, Patel AY, Allard Trout D, Xu E, Yakobian N, Hugo W, Howard JF, Sheu KM, Hoffmann A, Lechner MG, Su MA. Pathogenic TNF-a drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 2022. PMID: 35058362


  13. Peay HL, Do BT, Khosla N, Paramsothy P, Erickson SW, Lamb MM, Whitehead N, Fox DJ, Pandya S, Kinnett K, Wolff J, Howard JF. Role Attainment in Emerging Adulthood: Subjective Evaluation by Male Adolescents and Adults with Duchenne and Becker Muscular Dystrophy. Journal of neuromuscular diseases 2022. PMID: 35275556


  14. Tsai C, Howard JF, Mehrabyan A. A Case of MuSK Myasthenia Gravis Presenting With Persistent Respiratory Insufficiency. Journal of clinical neuromuscular disease 2021. PMID: 34431800


  15. Li Y, Yi JS, Howard JF, Chopra M, Russo MA, Guptill JT. Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clinical immunology (Orlando, Fla.) 2021. PMID: 34450290


  16. Guidon AC, Muppidi S, Nowak RJ, Guptill JT, Hehir MK, Ruzhansky K, Burton LB, Post D, Cutter G, Conwit R, Mejia NI, Kaminski HJ, Howard JF. Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE). Muscle & nerve 2021. PMID: 33959997


  17. Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R, ADAPT Investigator Study Group. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. Neurology 2021. PMID: 34146511


  18. Howard JF, Karam C, Yountz M, O'Brien FL, Mozaffar T, REGAIN Study Group. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Annals of clinical and translational neurology 2021. PMID: 34043280


  19. Howard JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, Farzaneh-Far R, Murai H, Wiendl H. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. Expert opinion on investigational drugs 2021. PMID: 33792453


  20. Guptill JT, Barfield R, Chan C, Russo MA, Emmett D, Raja S, Massey JM, Juel VC, Hobson-Webb LD, Gable KL, Gonzalez N, Hammett A, Howard JF, Chopra M, Kaminski HJ, Siddiqi ZA, Migdal M, Yi JS. Reduced plasmablast frequency is associated with seronegative myasthenia gravis. Muscle & nerve 2020. PMID: 33294984


  21. Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, Tavee JO, Kaminski H, Howard JF, Cutter G, Wiendl H, Maas MB, Illa I, Mantegazza R, Murai H, Utsugisawa K, Nowak RJ, CARE-MG Study Group. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). The Lancet. Neurology 2020. PMID: 33212055


  22. Nowak RJ, Muppidi S, Beydoun SR, O'Brien FL, Yountz M, Howard JF. Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. Frontiers in neurology 2020. PMID: 33329303


  23. Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF, REGAIN Study Group. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology 2020. PMID: 33229455


  24. Green JD, Barohn RJ, Bartoccion E, Benatar M, Blackmore D, Chaudhry V, Chopra M, Corse A, Dimachkie MM, Evoli A, Florence J, Freimer M, Howard JF, Jiwa T, Kaminski HJ, Kissel JT, Koopman WJ, Lipscomb B, Maestri M, Marino M, Massey JM, McVey A, Mezei MM, Muppidi S, Nicolle MW, Oger J, Pascuzzi RM, Pasnoor M, Pestronk A, Provenzano C, Ricciardi R, Richman DP, Rowin J, Sanders DB, Siddiqi Z, Soloway A, Wolfe GI, Wulf C, Drachman DB, Traynor BJ. Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ open 2020. PMID: 32948566


  25. Areson DG, Filer WG, Harris MG, Howard JF, Shuping LT, Traub R. Accuracy of the Scratch Collapse Test for Carpal Tunnel Syndrome in Comparison With Electrodiagnostic Studies. Hand (New York, N.Y.) 2020. PMID: 32698624


  26. Mantegazza R, O'Brien FL, Yountz M, Howard JF, REGAIN study group. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Annals of clinical and translational neurology 2020. PMID: 32700461


  27. Pittock SJ, Weitz I, Howard JF, Sabatella G, Mehta S, Franklin J. Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. CNS spectrums 2020. PMID: 32641193


  28. Rivner MH, Quarles BM, Pan JX, Yu Z, Howard JF, Corse A, Dimachkie MM, Jackson C, Vu T, Small G, Lisak RP, Belsh J, Lee I, Nowak RJ, Baute V, Scelsa S, Fernandes JA, Simmons Z, Swenson A, Barohn R, Sanka RB, Gooch C, Ubogu E, Caress J, Pasnoor M, Xu H, Mei L. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study. Muscle & nerve 2020. PMID: 32483837


  29. Albazli K, Kaminski HJ, Howard JF. Complement Inhibitor Therapy for Myasthenia Gravis. Frontiers in immunology 2020. PMID: 32582144


  30. Li Y, Guptill JT, Russo MA, Howard JF, Massey JM, Juel VC, Hobson-Webb LD, Emmett D, Chopra M, Raja S, Liu W, Yi JS. Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. Journal of neuroimmunology 2020. PMID: 32497931


  31. Jacob S, Murai H, Utsugisawa K, Nowak RJ, Wiendl H, Fujita KP, O'Brien F, Howard JF. Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Therapeutic advances in neurological disorders 2020. PMID: 32426038


  32. Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Zilucoplan MG Study Group, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA neurology 2020. PMID: 32065623


  33. International MG/COVID-19 Working Group, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal of the neurological sciences 2020. PMID: 32247193


  34. Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF, REGAIN study group. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. Journal of neurology 2020. PMID: 32189108


  35. Raja SM, Howard JF, Juel VC, Massey JM, Chopra M, Guptill JT. Clinical outcome measures following plasma exchange for MG exacerbation. Annals of clinical and translational neurology 2019. PMID: 31560178


  36. Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF, REGAIN Study Group. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2019. PMID: 31115842


  37. Howard JF, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM, Efgartigimod MG Study Group. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 2019. PMID: 31118245


  38. Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF, REGAIN Study Group. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2019. PMID: 30905021


  39. Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF, Regain Study Group. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle & nerve 2019. PMID: 30767274


  40. Clifford KM, Hobson-Webb LD, Benatar M, Burns TM, Barnett C, Silvestri NJ, Howard JF, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, Laboy SM, Fellman MA, Howard DB, Kolb NA, Greene SM, Pasnoor M, Dimachkie MM, Barohn RJ, Hehir MK. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle & nerve 2019. PMID: 30575980


  41. Li Y, Guptill JT, Russo MA, Massey JM, Juel VC, Hobson-Webb LD, Howard JF, Chopra M, Liu W, Yi JS. Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Experimental neurology 2018. PMID: 30472069


  42. Sabre L, Guptill JT, Russo M, Juel VC, Massey JM, Howard JF, Hobson-Webb LD, Punga AR. Circulating microRNA plasma profile in MuSK+ myasthenia gravis. Journal of neuroimmunology 2018. PMID: 30316681


  43. Allard DE, Wang Y, Li JJ, Conley B, Xu EW, Sailer D, Kimpston C, Notini R, Smith CJ, Koseoglu E, Starmer J, Zeng XL, Howard JF, Hoke A, Scherer SS, Su MA. Schwann cell-derived periostin promotes autoimmune peripheral polyneuropathy via macrophage recruitment. The Journal of clinical investigation 2018. PMID: 30222134


  44. Moore CJ, Caughey MC, Meyer DO, Emmett R, Jacobs C, Chopra M, Howard JF, Gallippi CM. In Vivo Viscoelastic Response (VisR) Ultrasound for Characterizing Mechanical Anisotropy in Lower-Limb Skeletal Muscles of Boys with and without Duchenne Muscular Dystrophy. Ultrasound in medicine & biology 2018. PMID: 30174231


  45. Vissing J, O'Brien F, Wang JJ, Howard JF. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study. Muscle & nerve 2018. PMID: 29684239


  46. Crow RA, Hart KA, McDermott MP, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Hirtz D, Lochmuller H, Straub V, Ciafaloni E, Shieh PB, Spinty S, Childs AM, Manzur AY, Morandi L, Butterfield RJ, Horrocks I, Roper H, Flanigan KM, Kuntz NL, Mah JK, Morrison L, Darras BT, von der Hagen M, Schara U, Wilichowski E, Mongini T, McDonald CM, Vita G, Barohn RJ, Finkel RS, Wicklund M, McMillan HJ, Hughes I, Pegoraro E, Bryan Burnette W, Howard JF, Thangarajh M, Campbell C, Griggs RC, Bushby K, Guglieri M. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial. Trials 2018. PMID: 29793540


  47. Howard JF, O'Brien F, Wang JJ. Distinct representation of muscle weakness in QMG and MG-ADL - Authors' reply. The Lancet. Neurology 2018. PMID: 29452680


  48. Smith CJ, Allard DE, Wang Y, Howard JF, Montgomery SA, Su MA. IL-10 Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4+ T Cell Migration. Journal of immunology (Baltimore, Md. : 1950) 2018. PMID: 29367208


  49. Howard JF. Myasthenia gravis: the role of complement at the neuromuscular junction. Annals of the New York Academy of Sciences 2017. PMID: 29266249


  50. Benatar M, Howard JF, Barohn R, Wolfe GI, Cutter G. Learning from the past: reflections on recently completed myasthenia gravis trials. Annals of the New York Academy of Sciences 2017. PMID: 29064567


  51. Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R, REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. The Lancet. Neurology 2017. PMID: 29066163


  52. Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF, Howard D, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, LaBoy SM, Fellman MA, Greene SM, Pasnoor M, Burns TM. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 2017. PMID: 28801338


  53. Lewis MJ, Howard JF, Olby NJ. The Relationship between Trans-Lesional Conduction, Motor Neuron Pool Excitability, and Motor Function in Dogs with Incomplete Recovery from Severe Spinal Cord Injury. Journal of neurotrauma 2017. PMID: 28462632


  54. Jovanovich EN, Howard JF. Brachial Plexus Injury in a 6-Year-Old Boy with 100% Displaced Proximal Humeral Metaphyseal Fracture: A Case Presentation. PM & R : the journal of injury, function, and rehabilitation 2017. PMID: 28606839


  55. Juel VC, Sanders DB, Hobson-Webb LD, Massey JM, Guptill JT, O'Brien F, Wang JJ, Howard JF. Marked clinical and jitter improvement after eculizumab in refractory myasthenia. Muscle & nerve 2017. PMID: 28214342


  56. Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Hirtz D, Shieh PB, Straub V, Childs AM, Ciafaloni E, Butterfield RJ, Horrocks I, Spinty S, Flanigan KM, Kuntz NL, Baranello G, Roper H, Morrison L, Mah JK, Manzur AY, McDonald CM, Schara U, von der Hagen M, Barohn RJ, Campbell C, Darras BT, Finkel RS, Vita G, Hughes I, Mongini T, Pegoraro E, Wicklund M, Wilichowski E, Bryan Burnette W, Howard JF, McMillan HJ, Thangarajh M, Griggs RC. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary clinical trials 2017. PMID: 28450193


  57. Howard JF, Freimer M, O'Brien F, Wang JJ, Collins SR, Kissel JT, MG (Phase2) Study Group. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis. Muscle & nerve 2017. PMID: 28010051


  58. Richards J, Howard JF. Seronegative myasthenia gravis associated with malignant thymoma. Neuromuscular disorders : NMD 2017. PMID: 28238572


  59. Guptill JT, Juel VC, Massey JM, Anderson AC, Chopra M, Yi JS, Esfandiari E, Buchanan T, Smith B, Atherfold P, Jones E, Howard JF. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity 2016. PMID: 27684107


  60. Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ, Methotrexate in MG Investigators of the Muscle Study Group. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology 2016. PMID: 27306628


  61. Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM, Hehir MK, Hobson-Webb LD, Howard JF, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle & nerve 2015. PMID: 26662952


  62. Beltran Papsdorf T, Howard JF, Chahin N. Late-onset Becker muscular dystrophy: Refining the clinical features and electrophysiological findings. Muscle & nerve 2015. PMID: 26179421


  63. Fan Z, Kocis K, Valley R, Howard JF, Chopra M, Chen Y, An H, Lin W, Muenzer J, Powers W. High-Pressure Transvenous Perfusion of the Upper Extremity in Human Muscular Dystrophy: A Safety Study with 0.9% Saline. Human gene therapy 2015. PMID: 25953425


  64. Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chi? A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ. A genome-wide association study of myasthenia gravis. JAMA neurology 2015. PMID: 25643325


  65. Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurology(R) neuroimmunology & neuroinflammation 2015. PMID: 25745635


  66. Beltran Papsdorf TB, Howard JF, Chahin N. Pearls & Oy-sters: clues to the diagnosis of adult-onset acid maltase deficiency. Neurology 2014. PMID: 24590251


  67. Parnell BA, Howard JF, Geller EJ. The effect of sacral neuromodulation on pudendal nerve function and female sexual function. Neurourology and Urodynamics 2014. PMID: 24615871


  68. Howard JF, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT, MG Study Group. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle & nerve 2013. PMID: 23512355


  69. Zeng XL, Nagavalli A, Smith CJ, Howard JF, Su MA. Divergent effects of T cell costimulation and inflammatory cytokine production on autoimmune peripheral neuropathy provoked by Aire deficiency. Journal of immunology (Baltimore, Md. : 1950) 2013. PMID: 23487421


  70. Howard JF. Electrodiagnosis of disorders of neuromuscular transmission. Physical medicine and rehabilitation clinics of North America 2012. PMID: 23177038


  71. Kornegay JN, Childers MK, Bogan DJ, Bogan JR, Nghiem P, Wang J, Fan Z, Howard JF, Schatzberg SJ, Dow JL, Grange RW, Styner MA, Hoffman EP, Wagner KR. The paradox of muscle hypertrophy in muscular dystrophy. Physical medicine and rehabilitation clinics of North America 2012. PMID: 22239881


  72. Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, Detwiler DA, Larsen CA, Grange RW, Bhavaraju-Sanka RK, Tou S, Keene BP, Howard JF, Wang J, Fan Z, Schatzberg SJ, Styner MA, Flanigan KM, Xiao X, Hoffman EP. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mammalian genome : official journal of the International Mammalian Genome Society 2012. PMID: 22218699


  73. Weig SG, Zinn MM, Howard JF. Idiopathic intracranial hypertension in a child with Duchenne muscular dystrophy. Pediatric neurology 2011. PMID: 22115006


  74. Fan Z, Kocis K, Valley R, Howard JF, Chopra M, An H, Lin W, Muenzer J, Powers W. Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy. Molecular therapy : the journal of the American Society of Gene Therapy 2011. PMID: 21772257


  75. Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng H, Wang B, Qiao C, Howard JF, Xiao X. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Molecular therapy : the journal of the American Society of Gene Therapy 2010. PMID: 20517298


  76. Donofrio PD, Berger A, Brannagan TH, Bromberg MB, Howard JF, Latov N, Quick A, Tandan R. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle & nerve 2009. PMID: 19768755


  77. Howard JF, Sanders DB. Chapter 12 Neurotoxicology of neuromuscular transmission. Handbook of clinical neurology 2008. PMID: 18631850


  78. Galano HR, Olby NJ, Howard JF, Shelton GD. Myokymia and neuromyotonia in a cat. Journal of the American Veterinary Medical Association 2005. PMID: 16313038


  79. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, Howard JF, Kinsella LJ, Latov N, Lewis RA, Low PA, Sumner AJ. Distal symmetrical polyneuropathy: a definition for clinical research. A report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Archives of physical medicine and rehabilitation 2005. PMID: 15641009


  80. Mareska MC, Adams KK, Muenzer J, Frerman F, Braun TG, Howard JF. Adult-Onset Presentation of Glutaric Acidemia Type II With Myopathy. Journal of clinical neuromuscular disease 2003. PMID: 19078703